On this week's episode we’ll discuss the findings from a long-term follow up study of fludarabine, cyclophosphamide, and rituximab in IGHV-mutated CLL, learn more about the impact of genetic alterations and minimal residual disease in adults with KMT2A-rearranged B-cell precursor ALL, and discuss a pre-clinical study of reinforced immunotherapy for myeloma using a new bispecific antibody-based approach.
View all episodes
By American Society of Hematology
4.1
4949 ratings
On this week's episode we’ll discuss the findings from a long-term follow up study of fludarabine, cyclophosphamide, and rituximab in IGHV-mutated CLL, learn more about the impact of genetic alterations and minimal residual disease in adults with KMT2A-rearranged B-cell precursor ALL, and discuss a pre-clinical study of reinforced immunotherapy for myeloma using a new bispecific antibody-based approach.
11,140 Listeners
141 Listeners
319 Listeners
500 Listeners
75 Listeners
26 Listeners
1,156 Listeners
2 Listeners
363 Listeners
373 Listeners
1 Listeners
48 Listeners
190 Listeners
30 Listeners
4 Listeners